Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2010Clinical Interventions in AgingOpen Access

Management of hyperuricemia in gout: focus on febuxostat

View Full Paper
Ask AI
Bookmark
Share

Authors

MRMark ReindersTJTim Jansen

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Reinders et al. (2010) studied this question.

synapsesocial.com/papers/6a76480c5db9de976abcbc6ehttps://doi.org/10.2147/cia.s5476
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial2004 · 186 citations
  2. 2Effect of urate‐lowering therapy on the velocity of size reduction of tophi in chronic gout2002 · 453 citations
  3. 3The Effect of Age and Gender on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase2008 · 57 citations
  4. 4Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout2005 · 50 citations